FDA decision: Zidesamtinib by Nuvalent (in 2026)

FDA decision on Zidesamtinib in 2026 If the FDA's decision on Zidesamtinib by Nuvalent in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Zidesamtinib (also known by its development code NVL-520) is an experimental cancer medicine made by Nuvalent Inc. that is designed to fight a specific type of lu